PTPI (Petros Pharmaceuticals, Inc.) Future Price to Earnings

Official company branding of Petros Pharmaceuticals, Inc. (PTPI)

Complex patent protections and regulations for transitioning drugs to over-the-counter status create significant barriers to entry in the men's health niche. The GURU.Markets terminal displays the projected price-to-earnings chart for Petros Pharmaceuticals (PTPI), where the current metric is 0.00. Stendra's strong pricing power and the digital transformation of sales ensure stability, although reliance on a single product and marketing limits create operational risks.

petrospharma.com - PTPI Market Cap to Future Earnings Ratio (period 07/04/2022 - 06/28/2025)

Summary analytical data breakdowns for petrospharma.com (PTPI)

- current price and projected stock value:
Fundamental valuation:PTPI Petros Pharmaceuticals, Inc.
Brand item of Petros Pharmaceuticals

When screening asset reliability, an investor utilizes the issuer's forward P/E, which determines the share price relative to expected earnings, reflecting market yield expectations. For Petros Pharmaceuticals (PTPI), this metric is critical, as pressure from low-cost generics limits pricing power, necessitating an assessment of branding effectiveness through the trend of forward multiples on the chart.

Competitor analysis for Petros Pharmaceuticals

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple Eupraxia Pharma (EPRX)|Future Price to Earnings BioHarvest Sciences Inc. BHST|EXOZ - Projected Price to Earnings|ORMP: Projected Price to Earnings|Future Price to Earnings Multiple ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio abvcpharma.com (ABVC)|Future Price to Earnings Cumberland Pharma|Future Price to Earnings QNTM|Forward P/E Multiple FGEN|TELO (Telomir Pharma) - Future Price to Earnings Multiple|Future Price to Earnings Rani Therapeutics Holdings RANI|SNYR - Projected Price to Earnings|RLYB - Future Price to Earnings|Market Cap to Projected Earnings lexariabioscience.com LEXX|PULM: Forward P/E Multiple|Price to Future Earnings Ratio PTHL|Future Price to Earnings Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Forward P/E Multiple IBO|Market Cap to Projected Earnings TNF Pharmaceuticals, Inc.|Forward P/E Multiple YCBD (cbdMD, Inc.)|PRFX (PainReform Corp) - Price to Expected Earnings Ratio|CYTO: Projected Price to Earnings|LIPO - Forward P/E Multiple|OptiNose, Inc. (OPTN) - Future Price to Earnings|PIRS - Market Cap to Projected Earnings|Future Price to Earnings Procaps|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP